9611s202
NM_001190440.1 NM_006311.3 XM_005256866.4 XM_005256868.4 XM_005256871.4 XM_005256872.4 XM_005256873.4 XM_005256874.4 XM_005256875.3 XM_006721601.3 XM_006721602.3 XM_006721603.3 XM_006721604.3 XM_011524083.2 XM_011524084.2 XM_011524085.2 XM_011524086.2 XM_017025396.1 XM_017025397.1 XM_017025398.1 XM_017025399.1 XM_017025400.1 XM_017025401.1 XM_017025402.1 XM_017025403.1 XM_017025404.1 XM_017025405.1 XM_017025406.1 XM_017025407.1 XM_017025408.1 XM_017025409.1 XM_017025410.1 XM_017025411.1 XM_017025412.1 XM_017025413.1 XM_017025414.1 XM_017025415.1 XM_017025416.1 XM_017025417.1 XM_017025418.1 XM_017025419.1 XM_017025420.1
10%(+/-3% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00196920_m1]
HeLa cells were reverse transfected with 5 nM gene-specific Silencer® Select siRNA or 5 nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, RNA was isolated, and then two-step, quantitative RT-PCR was performed using an appropriate TaqMan® Gene Expression Assay. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.